Ronald Bruehlman Acquires Shares in GoodRx Holdings

Ronald Bruehlman, an insider at GoodRx Holdings, Inc., bought 73,434 shares of the company on June 16, 2026. This transaction did not involve a planned purchase under a Rule 10b5-1 plan, and the shares were acquired at an unspecified price. GoodRx's stock was trading at $2.73 on the NasdaqGS at the time of the purchase.

Insider Buying and Selling at GoodRx Holdings, Inc.

On June 16, 2026, several insiders, including Ronald Bruehlman, acquired 73,434 shares each of GoodRx Holdings. Other insiders involved in the purchase were Douglas Joseph Hirsch, Kelly Kennedy, Scott Wagner, Agnes Rey-Giraud, and Trevor Bezdek. None of these transactions were part of a pre-planned trading program.

Other Institutional Activity in GoodRx Holdings

Institutional activity in GoodRx Holdings has seen mixed movements. Francisco Partners Management, LP, maintained its significant position with 60,078,184 shares valued at approximately $117.8 million. LSV Asset Management increased its holdings by 2,156,031 shares, ending with 4,981,931 shares worth about $9.8 million. Ameriprise Financial Inc. added 1,183,329 shares, bringing its total to 4,455,760 shares valued at roughly $8.7 million. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both established new positions, with 4,261,516 and 3,362,864 shares, valued at $8.4 million and $6.6 million, respectively.

GoodRx Holdings, Inc. Stock Down 26.1%

Shares of GoodRx Holdings, Inc. (NasdaqGS: GDRX) are trading near $2.73. The company has a market capitalization of $924.6 million, with a P/E ratio of 45.5 and a forward P/E of 7.6. The stock's beta is 1.615, indicating higher volatility compared to the market. Over the past year, the stock has seen a low of $1.77 and a high of $5.81. Its 50-day moving average is $2.54, while the 200-day moving average is $2.89.

Recent Earnings

GoodRx Holdings reported revenue of $787.9 million with a slight decline of 4.4% in revenue growth. The company posted an EPS of $0.06, with a net margin of 2.6% and a return on equity of 3.2%. The next earnings report is scheduled for August 5, 2026.

Analysts Set New Price Targets

Analysts have maintained various stances on GoodRx Holdings. On May 14, 2026, Citigroup maintained its buy rating with a $4.00 price target. Similarly, TD Cowen reaffirmed its buy rating with the same target on May 11, 2026. Meanwhile, Jefferies downgraded the stock to a hold on January 22, 2026, with a $2.75 target. The consensus rating is a hold, with an average target price of $3.18.

About GoodRx Holdings

GoodRx Holdings, Inc., based in Santa Monica, California, offers a platform that helps consumers compare prices and save on prescription drugs in the United States. The company provides a range of healthcare products and services, including subscription programs and telehealth services through GoodRx Care. Additionally, it offers solutions for pet medications and serves pharmacy benefit managers. GoodRx was founded in 2011 and is led by CEO Wendy Barnes.

Bottom Line

Ronald Bruehlman's recent purchase of GoodRx shares highlights insider confidence in the company. Investors often watch insider transactions for signals on company prospects. GoodRx's stock performance and analyst ratings suggest mixed sentiment. As always, it's important to remember that insider purchases and 13F filings reflect past actions and may not indicate future performance.